LONDON, April 21, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Amgen Inc. (NASDAQ: AMGN), PDL BioPharma Inc. (NASDAQ: PDLI), Amarin Corporation PLC (NASDAQ: AMRN), and Pharmacyclics Inc. (NASDAQ: PCYC). Free research report on Celgene can be accessed at http://get.Investor-Edge.com/pdf/?c=Celgene&d=21-Apr-2015&s=CELG. On Monday, April 20, 2015, the NASDAQ Composite ended at 4,994.60, up 1.27%, the Dow Jones Industrial Average advanced 1.17%, to finish the day at 18,034.93, and the S&P 500 closed at 2,100.40, up 0.92%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 852.00, up 0.54%, with the index also advancing 4.67% in the previous three months. Register for your complimentary reports at the links given below.
Celgene Corp.'s stock finished Monday's session 1.13% higher at $114.75. A total of 4.47 million shares were traded, which was below its three months average volume of 5.46 million shares. The stock moved between $113.03 and $114.77 during the session. Over the previous three trading sessions and the last three months, Celgene Corp.'s shares have fallen by 2.94% and 6.90%, respectively. However, from the beginning of 2015, the stock has gained 2.58%. The company's shares are trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $118.86 is greater than its 200-day moving average of $105.54. Celgene Corp.'s stock traded at a PE ratio of 44.86 and has a Relative Strength Index (RSI) of 41.25. Sign up and read the free notes on CELG at:
On Monday, shares in Amgen Inc. fluctuated between $163.06 and $166.05 before ending the session 1.46% higher at $165.97. The stock reported a trading volume of 2.75 million shares, below its three months average volume of 3.42 million shares. Shares of the company traded at a PE ratio of 22.73. Amgen Inc.'s shares have advanced 0.30% in the previous three trading sessions, 5.31% in the last three months and 4.19% on YTD basis. The company is trading above its 50-day and 200-day moving averages of $158.94 and $148.73, respectively. Moreover, shares of Amgen Inc. have an RSI of 54.49. The complimentary notes on AMGN can be downloaded as in PDF format at:
PDL BioPharma Inc.'s stock edged 0.42% lower, to close the day at $7.15. The stock recorded a trading volume of 3.59 million shares, below its three months average volume of 3.73 million shares. The stock oscillated between $7.09 and $7.20 during the session. Over the last three trading sessions and over the past one month, PDL BioPharma Inc.'s shares have fallen by 1.99% and 1.92%, respectively. Further, the stock has lost 7.26% since the start of this year. The company is trading above its 50-day moving average of $7.12, while the 50-day moving average is below PDL BioPharma Inc.'s 200-day moving average of $8.09. Additionally, the stock traded at a PE ratio of 3.74 and has an RSI of 51.88. Register for free on Investor-Edge and access the latest research on PDLI at:
On Monday, shares in Amarin Corp. PLC recorded a trading volume of 1.24 million shares, lower than its three months average volume of 5.14 million shares. The stock ended the day at $2.29, which was 1.72% below its previous day's closing of $2.33, and registered an intraday range of $2.28 and $2.38. Although Amarin Corp. PLC's shares have lost 5.37% in the previous three trading sessions, it has surged 124.51% in the last three months and 133.75% on YTD basis. The company is trading above its 50-day and 200-day moving averages of $1.97 and $1.46, respectively. Furthermore, shares of Amarin Corp. PLC have an RSI of 50.91. The complete research on AMRN is available for free at:
Pharmacyclics Inc.'s stock edged 0.34% lower, to close Monday's session at $256.57, after oscillating between $256.30 and $258.35. The stock recorded a trading volume of 0.73 million shares, below its three months average volume of 1.61 million shares. Over the last three months and since the beginning of this year, Pharmacyclics Inc.'s shares have rallied 68.12% and 109.86%, respectively. However, the stock has lost 0.50% in the last one month. The company is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $229.69 is above its 200-day moving average of $151.24. Further, Pharmacyclics Inc.'s stock traded at a PE ratio of 237.56 and has an RSI of 72.11. Free in depth research on PCYC is available at:
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.